36results about How to "Strong target specificity" patented technology

The present invention discloses a construction method of LRFFT1 cells. The construction method of the LRFFT1 cells comprises the following steps: ctDNA sequencing of human peripheral blood or whole exon sequencing of tumor tissues is conducted to screen out mutation sites for antigen epitope prediction, and a mutant polypeptide expression gene sequence is ligated and synthesized; simultaneously alentiviral vector is constructed, lentiviruses are packaged, the packaged lentiviruses transfect APC cells, modification of specific LV cells is completed, the APC cells are co-cultured with PBMC isolated from peripheral blood in vitro, effective peptides are screened out, and ordinary T cells are transformed into RFF cells with a more precise killing ability by a second impact of a precise and effective peptide stimulation; then a TCR-T technology principle is used to conduct modification; and the modified T cells are then subjected to a gene-editing technology to conduct knocking out of immunosuppressive targets, the T cells with the specific killing ability is precisely protected from in vivo inhibition, the killing ability of the T cells on tumor cells is improved, and the LRFFT1 cellsmore combining attack and defense are obtained.

The invention belongs to the field of biotechnology and particularly relates to an AFFT2 cell and a preparation method of the AFFT2 cell. The cell is transformed through the TCR-T technology, the transformed T cell is closed in vitro through an inhibitory signal molecular antibody drug, so that the anti-tumor capability of the T cell is improved effectively, and among the cell transformed throughthe AFFT2 scheme, the proportion of the specific T cell capable of recognizing a tumor antigen is more than 70%.

The invention relates to an MRFFT1 cell and a preparation method of the MRFFT1 cell, a mutation polypeptide is screened through the predication of an epitope, the sequence of an expression gene of themutation polypeptide is connected and synthesized; meanwhile, an MVA virus vector is constructed, an MVA virus is packaged, an APC (Antigen Presenting Cell) is transfected, the transformation of a specific MV cell is finished, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common Tcell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformation is conducted through the TCR-T technical principle; an immunosuppressive target of the transformed T cell is knocked off through the gene editing technology, the specific lethal T cell is protected accurately against in-vivo suppression, and the lethality of the T cell on a tumor cell is improved.

The invention discloses an LRFFT2 cell. According to the LRFFT2 cell, human peripheral blood is used for carrying out ctDNA sequencing or carrying out whole exome sequencing on tumor tissue, mutationsites are screened out for antigen epitope prediction, and mutant polypeptide expression gene sequences are connected and synthesized; meanwhile, a lentivirus vector is constructed, lentivirus is packaged, an APC cell is transfected, the modification of a specific LV cell is completed, co-culture is carried out with a PBMC separated from the peripheral blood in vitro, effective polypeptide is screened out, and the second impact of stimulation of the effective polypeptide is accurate, so that a common T cell is transformed into an RFF cell with more accurate killing capability; transformation is carried out by utilizing a TCR-T technical principle; and immunosuppressive signal sealing is carried out on the transformed T cell in vitro by using an antibody drug, so that the specific killing Tcell is accurately protected from in-vivo suppression, and the killing force of the T cell on a tumor cell is improved, and therefore the LRFFT2 cell with better attack and defense functions is obtained. The LRFFT2 cell can be widely applied to individualized accurate treatment of solid tumors.

The invention belongs to the field of biotechnology, and particularly relates to a construction method of HAFFT1 cells. According to the method, small-molecule-modified polypeptide-stimulated cells are modified through a TCR-T technology. The modified T cells are subjected to immunosuppressive target pot knockout, specific killer T cells are accurately protected and prevented from inhibition in vivo, and the killing ability of the T cells to cancer cells is improved. The proportion of specific T cells (TCR+) recognizing tumor antigens is more than 80% in the HAFFT1 modified cells.

CtDNA sequencing of human-derived peripheral blood or whole exon sequencing of tumor tissues is carried out to screen a mutation site for antigen epitope prediction, and the mutation site undergoes antigen epitope prediction to ligate and synthesize a mutant polypeptide expression gene sequence; construction of a lentiviral vector and packaging of the lentivirus are simultaneously carried out, anAPC cell is transferred, the transformation of a specific LV cell is completed, an in vitro PBMC and a PBMC isolated from peripheral blood are co-cultured, an effective peptide is screened, and an ordinary T cell is transformed through accurate and effective peptide stimulated secondary impact to form an RFF cell having an accurate killing capability; transformation is carried out by using a TCR-Ttechnology principle; and the modified T cell undergoes immunosuppressive target knockout by using a gene editing technology, so a specific killer T cell is accurately protected from being inhibitedin vivo, the lethality of the T cell on tumor cells is improved, and the offensive and defensive LRFFT1 cell is obtained.

The invention provides a construction method of LRFFT2 cells; human peripheral blood is used for ctDNA sequencing or tumor tissues are used for full exon sequencing, mutant sites are screened out forepitope prediction and are connected to synthesize a mutant polypeptide expression gene sequence; at the same time, a lentivirus vector is constructed, lentiviruses are packaged, APC cells are transfected, the transformation of specific LV cells is completed, the transformed specific LV cells are co-cultured with PBMC isolated from the peripheral blood in vitro, and effective polypeptides are screened out; through precise effective second shocking stimulated by the polypeptides, ordinary T cells are transformed into RFF cells with more precise killing ability; transformation is preformed by aTCR-T technical principle; the transformed T cells are subjected to immunosuppressive signal sealing with antibody drugs in vitro, the specific killer T cells are precisely protected from inhibition in vivo, the killing ability of the T cells to tumor cells is improved, and the LRFFT2 cells with both attack and defense are obtained. The LRFFT2 cells can be widely applied in individualized and precise treatment of solid tumors.

Patient peripheral blood is used for ctDNA sequencing or tumor tissue is used for whole exon sequencing, mutation sites are screened to be subjected to epitope presequencing, and connection and synthesis are performed to obtain a mutation polypeptide expression gene order. Besides, a retroviral vector is constructed, slow viruses are packed, APC cells are transfected, and reformation of specificity LV cells is completed. PBMC obtained by in vitro and peripheral blood separation is cocultured, effective pinpoint polypeptide is screened, and through second impact of pinpoint polypeptide stimulation, common T cells are reformed to obtain LRFF cells having pinpoint killing capacity, and the killing capacity of the T cells to tumor cells can be improved. The LRFF provided by the invention can be widely applied to individual pinpoint treatment of solid tumors.

The invention relates to a production method of an oriented nanofiber membrane-embedded micro-fluidic chip. The method comprises the following steps: carrying out electrostatic spinning and steam crosslinking on a PEI / PVA spinning solution to obtain an oriented PEI / PVA nanofiber membrane; modifying the surface of the oriented PEI / PVA nanofiber membrane with zwitterionic MPC and a targeting ligand Cys-PEG-FA to obtain PEI / PVA-PMPC-FA; and carrying out plasma bonding on the PEI / PVA-PMPC-FA and a herringbone PDMS micro-fluidic chip to obtain the oriented nanofiber membrane-embedded micro-fluidic chip which can be used for sorting circulating tumor cells. The oriented nanofiber membrane-embedded micro-fluidic chip is simple to operate, can rapidly realize the highly-pure capture and rapid release of the circulating tumor cells in blood, endows the nanofiber membrane with excellent anti-protein and anti-blood cell adhesion performances through amphion modification to improve the cell capture purity, and reduces the non-specific adhesion of blood cells through the oriented nanofiber membrane in order to further improve the capture purity, so the oriented nanofiber membrane-embedded micro-fluidic chip has a wide application prospect.

The application relates to AFFT1 cell and a preparation method thereof. The RFF cell is reformed by using TCR-T technical principle, the knock-out of the immunosuppression target spot is performed onthe reformed T cell by using gene editing technology, the condition that the specific lysis T cell is prevented from in-vivo suppression is precisely protected, and the lethality on the tumor cell bythe T cell is improved.

The invention relates to an MRFFT2 cell and a preparation method thereof. Mutant polypeptides are screened by antigen epitope prediction, and are ligated to synthesize a mutant polypeptide expressiongene sequence; an MVA virus vector is constructed, an MVA virus is packaged, an APC cell is transferred, the transformation of a specific MV cell is completed, in vitro PBMC and a PBMC isolated from peripheral blood are co-cultured, an effective peptide is screened, an ordinary T cell is transformed through accurate and effective peptide stimulated secondary impact to form an RFF cell having an accurate killing capability, transformation is carried out by using a TCR-T technology principle, the modified T cell undergoes immunosuppressive signal closing by using antibody drug in vitro, so a specific killer T cell is accurately protected from being inhibited in vivo, and the lethality of the T cell on tumor cells is improved.

The invention relates to a preparation method of AFFT1 cells. RFF cells are transformed through a TCR-T technical principle, then immunosuppression target spots of transformed T cells are knocked outthrough a gene editing technology, thus the specific cytotoxic T cells are precisely protected against being inhibited in vivo, and the lethality of the T cells on tumor cells is improved.

The invention belongs to the field of biotechnology, and in particular relates to a HAFFT1 cell and a preparation method thereof. The cells are modified with TCR-T technology, and the modified T cells are then knocked out of immunosuppressive targets, which precisely protects the specific killer T cells from inhibition in vivo and improves the lethality of T cells against tumor cells . The proportion of specific T cells (TCR+) that recognize tumor antigens in the cells transformed by the HAFFT1 program is over 80%.

The invention belongs to the field of biotechnology, and in particular relates to a method for constructing AFFT2 cells. This method transforms cells with TCR-T technology, and the transformed T cells are blocked in vitro with inhibitory signal molecule antibody drugs, thereby effectively improving the anti-tumor ability of T cells. Cells transformed by the AFFT2 program can recognize tumor antigens The proportion of specific T cells is above 70%.

The invention belongs to the field of biotechnology, and in particular relates to a method for constructing HAFFT1 cells. In this method, cells stimulated by small molecule-modified polypeptides are transformed with TCR-T technology, and the transformed T cells are then knocked out immunosuppressive targets, which accurately protects specific killer T cells from in vivo. Inhibition increases the killing power of T cells to tumor cells. The proportion of specific T cells (TCR+) recognizing tumor antigens in cells transformed by the HAFFT1 program was over 80%.